Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
224 words
Compounds of general formula (I) wherein R represents H or C₁₋₆ alkyl; R₁ and R₂ represent H, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxycarbonyl, carboxyl, hydroxy, nitro, cyano, optionally C₁₋₄ alkyl mono- or disubstituted carbamoyl, optionally C₁₋₄ alkyl mono- or disubstituted amino, C₁₋₆ acylamino, C₁₋₄ alkoxy carbonylamino, C₁₋₆ alkylsulphynyl, C₁₋₆ alkylsulphonyl, C₁₋₆ acyl; R₃ represents H, C₁₋₆ alkyl, aryl, aralkyl or it may be absent; A represents CO, C = S, S -> O or B represents nitrogen when R₃ is absent and the B-D bond is single, or it is carbon; D represents CO, CH₂-CH₂, when the B-D bond is single, or D is C-R when the D-B bond is double, in which R₄ represents H, C₁₋₆ alkyl, aryl, aralkyl, hydroxy, C₁₋₄ alkoxy and R₅ represents H; X represents oxygen, N-R or it is absent; Y represents a basic group selected from: in which n is 2 or 3; p is 0 or 1 at the same time or not; q is 0, 2 or 3; R₆ and R₇ may be at the same time or not H, C₁₋₄ alkyl, aralkyl or, when R₇ is H or C₁₋₄ alkyl, R₆ may be in which R₈ represents H, C₁₋₄ alkyl or amino and all optical isomers, tautomeric forms and mixtures thereof, and the acid addition salts, internal salts or quaternary derivatives thereof.
Claim 2
Dependent Claim
224 words
Compounds of general formula (I) wherein R represents H or C₁₋₆ alkyl; R₁ and R₂ represent H, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxycarbonyl, carboxyl, hydroxy, nitro, cyano, optionally C₁₋₄ alkyl mono- or disubstituted carbamoyl, optionally C₁₋₄ alkyl mono- or disubstituted amino, C₁₋₆ acylamino, C₁₋₄ alkoxy carbonylamino, C₁₋₆ alkylsulphynyl, C₁₋₆ alkylsulphonyl, C₁₋₆ acyl; R₃ represents H, C₁₋₆ alkyl, aryl, aralkyl or it may be absent; A represents CO, C = S, S -> O or B represents nitrogen when R₃ is absent and the B-D bond is single, or it is carbon; D represents CO, CH₂-CH₂, when the B-D bond is single, or D is C-R when the D-B bond is double, in which R₄ represents H, C₁₋₆ alkyl, aryl, aralkyl, hydroxy, C₁₋₄ alkoxy and R₅ represents H; X represents oxygen, N-R or it is absent; Y represents a basic group selected from: in which n is 2 or 3; p is 0 or 1 at the same time or not; q is 0, 2 or 3; R₆ and R₇ may be at the same time or not H, C₁₋₄ alkyl, aralkyl or, when R₇ is H or C₁₋₄ alkyl, R₆ may be in which R₈ represents H, C₁₋₄ alkyl or amino and all optical isomers, tautomeric forms and mixtures thereof, and the acid addition salts, internal salts or quaternary derivatives thereof.
Claim 3
Dependent Claim
52 words
Compounds of general formula (I) according to claim 1, characterized in that Y represents endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl and endo-9-methyl-9-azabicylco[3.2.1]oct-3-yl, B is nitrogen, R is hydrogen, R₃ is absent, the B-D bond is single and R₁, R₂ D, X are as defined in claim 1, tautomers thereof and/or acid addition salts of the aforesaid compounds.
Claim 4
Dependent Claim
17 words
Physiologically acceptable acid addition salts of compounds of general formula (I) according to claims 1 and 2.
Claim 5
Dependent Claim
14 words
Salts according to claim 3 formed with hydrochloric, hydrobromic, citric, tartaric or benzenesulphonic acid.
Claim 6
Dependent Claim
31 words
The compound of formula (I) selected from: 1,4-dihydro-2(H)-2-oxo-3-quinazoline carboxylic acid-(endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl), ester N-(endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1,4-dihydro-2(H)-2-oxo-quinazoline-3-carboxamide 7-chloro-1,4-dihydro-2(H)-2-oxo-3-quinazoline carboxylic acid-(endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl), ester 1,4-dihydro-6-fluoro-2(H)-2-oxo-3-quinazoline carboxylic acid-(endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl), ester 1,4-dihydro-4-hydroxy-2(H)-2-oxo-3-quinazoline carboxylic acid-(endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl), ester and physiologically acceptable acid addition salts thereof.
Claim 7
Dependent Claim
31 words
The compound of formula (I) selected from: 1,4-dihydro-2(H)-2-oxo-3-quinazoline carboxylic acid-(endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl), ester N-(endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1,4-dihydro-2(H)-2-oxo-quinazoline-3-carboxamide 7-chloro-1,4-dihydro-2(H)-2-oxo-3-quinazoline carboxylic acid-(endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl), ester 1,4-dihydro-6-fluoro-2(H)-2-oxo-3-quinazoline carboxylic acid-(endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl), ester 1,4-dihydro-4-hydroxy-2(H)-2-oxo-3-quinazoline carboxylic acid-(endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl), ester and physiologically acceptable acid addition salts thereof.
Claim 8
Dependent Claim
109 words
Process for the preparation of compounds of general formula (I) according to claim 1, characterized in that a compound of general formula (II) in which R, R₁, R₂, R₃, A, B and D are as defined in claim 1, previously activated to a reactive derivative of general formula (IV) wherein M is a metal atom selected from lithium, sodium or potassium by an activating agent, is reacted with a compound of formula (III) Q - - X - Y (III) in which X and Y are as defined in claim 1, and Q is a leaving group, in an aprotic solvent at a temperature between -50°C and room temperature.
Claim 9
Dependent Claim
21 words
Process according to claim 6, characterized in that the activating agent is selected from n-butyllithium, lithium diisopropylamide (LDA) or sodium hydride.
Claim 10
Dependent Claim
17 words
Process according to claim 6, characterized in that the leaving group is selected from chlorine, methoxy, ethoxy.
Claim 11
Dependent Claim
85 words
Process for the preparation of compounds of general formula (I) according to claim 1, characterized in that, when B is carbon and X is oxygen or N - R, a compound of formula (V) in which R, R₁, R₂, R₃, A and D are as defined in claim 1, and Q is hydroxyl or any group as defined in claim 8, is reacted with a compound of formula (VI) H - X - Y (VI) wherein X and Y are as defined in claim 1.
Claim 12
Dependent Claim
39 words
Process according to claim 9, characterized in that, when Q is hydroxyl, the reaction is carried out in an inert aprotic solvent and in the presence of a suitable condensing agent and optionally in the presence of a catalyst.
Claim 13
Dependent Claim
46 words
Process according to claim 9, characterized in that, when Q is chlorine, the reaction is carried out in an inert aprotic solvent, optionally in the presence of an organic or inorganic acid acceptor at a temperature between -10°C and the boiling point of the selected solvent.
Claim 14
Dependent Claim
38 words
Process according to claim 9, characterized in that, when Q is methoxy or ethoxy, the reaction is carried out in an inert solvent capable of azeotropically removing the alcohol formed QOH, optionally in the presence of a catalyst.
Claim 15
Dependent Claim
30 words
Process according to claim 9, characterized in that the compounds of formula (VI) is reacted as its reactive derivative when X is oxygen at a temperature between 0° and 80°C.
Claim 16
Dependent Claim
95 words
Process for the preparation of compounds of general formula (I) according to claim 1, characterized in that, when B is nitrogen, R is hydrogen and R₃ is absent, a compound of general formula (VII) in which R₁, R₂, D, X and Y are as defined in claim 1, is reacted with a compound of general formula (VIII) Q₁ - - Q₂ (VIII) wherein Q₁ and Q₂, identical or different from each other are leaving groups, in an aprotic solvent and optionally in the presence of an acid acceptor at a temperature between 20° and 100°C.
Claim 17
Dependent Claim
20 words
Process according to claim 14, characterized in that the leaving groups are selected from chlorine, ethoxy, phenoxy, trichloromethoxy or imidazolyl.
Claim 18
Dependent Claim
39 words
Pharmaceutical compositions comprising as active ingredient at least one compound of general formula (I), as defined in claim 1, or a tautomer or phisiologically acceptable acid addition salts thereof, in association with a pharmaceutical acceptable carrier, diluent or excipient.
Claim 19
Dependent Claim
34 words
Pharmaceutical compositions according to claim 16 for the use in the treatment of patients suffering from disorders of gastrointestinal tract and in particular from peptic ulcer disease, irritablhe bowel syndrome, spastic constipation, cardiospasm, pylorospasm.
Claim 20
Dependent Claim
34 words
Pharmaceutical compositions according to claim 16 for the use in the treatment of patients suffering from obstructive acute and chronic spastic disorders of the respiratory tract, in particular in bronchoconstriction, chronic bronchitis, emphysema, asthma.
Claim 21
Dependent Claim
30 words
Pharmaceutical compositions according to claim 16 for the use in the treatment of patients suffering from spastic disorders of urinary and biliary tracts and in the treatment of urinary incontinence.